CONTRAST-INDUCED NEPHROPATHY IN CARDIOLOGY PRACTICE
Abstract
Contrast-induced nephropathy (CIN) is an important problem in cardiology practice, due to the wide use of contrast-based diagnostic and therapeutic interventions in cardiac patients. Despite the high annual rates of coronary angiography and various coronary interventions, the problem of contrast-induced renal complications has not been adequately addressed and controlled. This literature review describes the link between CIN and increased risk of morbidity, mortality, and extended hospitalization. Based on the published data, the prevalence of CIN is assessed, and the major pathogenetic mechanisms of CIN are presented, with an emphasis on CIN risk factors. The methods for correction of modifiable risk factors are proposed, as an approach towards CIN prevention. In addition, modern strategies of CIN prevention and their effectiveness are analysed.
About the Authors
O. I. Turenko
ГУЗ “Городская клиническая больница №15 им. О.М.Филатова” ДЗ
ОУ ВПО “Российский государственный медицинский университет Росздрава”, кафедра госпитальной терапии №1 лечебного факультета
Russian Federation
Russian Federation
A. Yu. Lebedeva
ГУЗ “Городская клиническая больница №15 им. О.М.Филатова” ДЗ
Russian Federation
Russian Federation
I. G. Gordeev
ОУ ВПО “Российский государственный медицинский университет Росздрава”, кафедра госпитальной терапии №1 лечебного факультета
Russian Federation
Russian Federation
N. A. Volov
ОУ ВПО “Российский государственный медицинский университет Росздрава”, кафедра госпитальной терапии №1 лечебного факультета
Russian Federation
Russian Federation
References
1. Волгина Г.В. Контраст – индуцированная нефропатия. Эпидемиология, факторы, риска, патофизиология// Радиология – практика 2007; 6: 42- 53.
2. Волгина Г.В. Контраст-индуцированная нефропатия: патогенез, факторы риска, стратегия профилактики// Нефрология и диализ 2006; Т.8, №2; 176-183.
3. Зайцева Н.В., Шамхалова М.Ш., Шестакова М.В. и др. Факторы риска развития и пути профилактики контрастиндуцированной нефропатии при проведении коронарной ангиографии у больных сахарным диабетом 2 типа//Сахарный диабет 2008; 2: 28 – 31.
4. Киселева О.А., Усенко А.Н., Сидорова Е.Е. и др. Деформационные свойства эритроцитов человека в присутствии рентгеноконтрастных средств// Экспериментальная и клиническая фармакология 2009;72: 33-35.
5. Шимановский Н.Л. Контрастные средства. 2009; 104-147.
6. Alamartine E., Phayphet M., Thibaudin d. et al. Contrast medium – induced acute renal failure and cholesterol embolism after radiological procedures: incidence, risk factors, and compliance with recommendations// Eur. J. Intern. Med. 2003; 14:426-431.
7. Alexopoulos E., Spargias K., Kyrzopoulos S. et al. Contrast – induced acute kidney injury in patients with renal dysfunction undergoing a coronary procedure and receiving nonionic low – osmolar versus iso – osmolar contrast media // Am. J. Med. Sci. 2010; 339: 25-30.
8. Aspelin P., Aubry P., Fransson S.G., et al. Nephrotoxic effects in high-risk patients undergoing angiography // N. Engl. Med. 2003;348: 491-499.
9. Bader B.D., Berger E.D., Heede M.B., et al. What is the best hydration regimen to prevent contrast media-induced nephrotoxicity?// Clin Nephrol 2004;62:1-7.
10. Bagshaw S.M., Ghali W.A. Theophylline for prevention of contrast-induced nephropathy: A systemic review and meta-analysis//Arch Intern Med 2005; 165: 1087-1093.
11. Baliga R., Ueda N., Walker P.D. et al. Oxidant mechanisms in toxic acute renal failure. Am. J. Kidney Dis. 1997; 29: 465-477.
12. Bartholomew B.A., Harjai K.J., Dukkipati S. et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification// Am. J. Cardiol. 2004; 93: 1515-1519.
13. Bartorelli A.B., Marenzi G. Contrast – induced nephropathy 2006; 3 – 13.
14. Bertrand M.E., Esplugas E., Piessens J. et al. Influence of a nonionic, isoosmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: А multicenter, randomized, double-blind study// Visipaque in Percutaneous Transluminal Coronary Angioplasty VIP Trial Investigators// Circulation 2000; 101: 131-136.
15. Brick R., Krzossos S., Markowetz F., et al. Acetylcysteine for prevention of contrast nephropathy: meta – analysis// Lancet 2003;362:598-603.
16. Briguori C., Colombo A., Violante A. et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity//European Heart J. 2004; 25: 206-211.
17. Briguori C., Manganelli F., Scarpato P., et al. Acetylcysteine and contrast agent – associated nephrotoxicity// J.Am. Coll. Cardiol. 2002; 40:298-303.
18. Chong E., Poh K.K., Liang S. et al. Risk factors and clinical outcomes for contrast – induced nephropathy after percutaneous coronary interventions in patients with normal serum creatinine// Ann Acad Med Singapore. 2010; 39(5):374-380
19. Corot C., Chronos N., Sabattier V. In vitro comparison of the effects of contrast media on coagulation and platelet activation// Blood Coagul Fibrinolysis 1996; 7: 602-608.
20. Davidson C.J., Laskey W.K., Hermiller J.B. et al. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial// Circulation 2000; 101: 2172-2177.
21. Diaz-Sandoval L.J., Kosowsky B.D., Losordo D.W. Acetylcystein to prevent angiography-related renal tissue injury (the apart trial)//Am J Cardiol 2002;89:356-358.
22. Durham J.D., Caputo C., Dokko J.H., et al. A randomized controlled trial of N-Acetylcystein to prevent contrast nephropathy in cardiac cardiography// Kidney Int 2002;62:2202-2207.
23. Dussol B., Morange S., Loundoun A. et al. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients//Nephrology Dialysis Transplantation. 2006; 21(8): 2120-2126.
24. Freeman R.V., O`Donnell M., Share D. et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose//Am J Cardiol 2002;90:1068-1073.
25. Gare M., Havis Y.S., Ben-Yehuda A. et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angio-graph// J Am Coll Cardiol 1999;34:1682-1688.
26. Grossman P.M., Gurm H.S., McNamara R. et al. Percutaneous coronary intervention complications and guide catheter size: bigger is not better// JACC Cardiovasc. Interv. 2009; 2: 636 -644.
27. Gupta R., Birnbaum Y., Yretsky B.F. The renal patient with coronary arteri disease. Current conceps and dilemmas//J. Am. Coll. Cardiol. 2004; 44: 1343-1353.
28. Heinrich M.C., Haberle L., Muller V. et al. Nephrotoxicity of iso – osmolar iodixanol compared with nonionic low-osmolar contrast media: meta – analysis of randomized controlled trials// Radiology 2009; 250: 68-86.
29. Heupler F.A Jr. Guidelines for performing angiography in patients taking metformin. Members of the Laboratory Performance Standards Committee of the Society for Cardiac Angiography and Interventions// Cathet. Cardiovasc. Diagn. 1998; 43:121-123.
30. Huber W., Eckel F., Hennig M., et al. Prophylaxis of contrast material induced nephropathy in patients in intensive care: acetylcystein, theophylline, or both? A randomized study// Radiology 2006 239:793-804.
31. Huber W., Ilgmann K., Page M., et al. Effect of theophylline on contrast-material induced nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study// Radiology.2002.223:772-779.
32. Kelly A.M., Dwamena B., Cronin P. Meta – analysis: Effectiveness of drugs for preventing contrast-induced nephropathy// Ann Intern Med 2008 148:284-294.
33. Khanal S., Attallah N., Smith D.E. et al. Statin therapy reduces contrast induced nephropathy: An analysis of contemporary PCI// Am J Med 2005;118:843-849.
34. Khoury Z., Schlicht J.R., Como J. et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media// Pharmacotherapy 1995;15:59-65.
35. Kurnik B.R., Allgren R.L., Genter F.C. et al. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy//Am J Kidney Dis 1998;31: 674-680.
36. Lancelot E., Idee J.P., Lacledere C. et al. Effects of two diametric iodinated contrast media on renal medullary blood perfusion and oxygenation in dogs// Radiol. 2002; 37:368-375.
37. Lindsay J., Apple S., Pinnow E.E. et al. Percytaneous coronary interventions – associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creati-nine//Catheter Cardiovasc Interv 2003; 59:338-343.
38. Manske C.L., Sprafka J.M., Strony J.T. et al. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990;89(5): 615-620.
39. Marenzi G., Assaneli E., Campodonico J. et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast – induced nephropathy and mortality //Ann. Intern. Med. 2009; 150: 170 -177.
40. Marenzi G., Lauri G., Campodonico J. et al. Comparison of two hemofiltration protocols for prevention of contrast – induced nephropathy in high – risk patients//Am J Med. 2006; 119(2): 155-162.
Review
For citations:
Turenko O.I., Lebedeva A.Yu., Gordeev I.G., Volov N.A. CONTRAST-INDUCED NEPHROPATHY IN CARDIOLOGY PRACTICE. Russian Journal of Cardiology. 2011;(3):78-86. (In Russ.)
Views:
465
Email this article 